Related Experiment Videos
In vitro antisickling activity of cromolyn sodium
A B Fall1, M Toppet, A Ferster
1Laboratoire de Pharmacognosie et Bromatologie, Institut de Pharmacie de l'Université Libre de Bruxelles, Belgium.
British Journal of Haematology
|January 14, 1999
Summary
Cromolyn sodium shows significant antisickling activity in vitro for sickle cell disease (SCD) patients. This suggests it may be a promising therapeutic candidate for further clinical investigation.
Area of Science:
- Hematology
- Pharmacology
Background:
- Sickle cell disease (SCD) is a debilitating genetic blood disorder.
- Current therapies for SCD have limitations, necessitating novel treatment strategies.
Purpose of the Study:
- To investigate the in vitro antisickling activity of cromolyn sodium.
- To compare the efficacy of cromolyn sodium against pentoxifylline, a standard treatment.
Main Methods:
- Blood samples were collected from 15 children with severe SCD.
- The number of sickle cells was quantified under deoxygenated conditions.
- Cromolyn sodium was tested at eight different concentrations.
Main Results:
- Cromolyn sodium demonstrated significantly higher antisickling activity compared to pentoxifylline.
- The effect was observed across all tested concentrations of cromolyn sodium.
Conclusions:
- Cromolyn sodium exhibits potent in vitro antisickling properties.
- It represents a promising therapeutic agent for sickle cell disease.
- Further in vivo studies are warranted to confirm its clinical efficacy.